Charles River Laboratories reported a 6.4% increase in revenue for the second quarter of 2022, reaching $973.1 million. GAAP earnings per share were $2.13, and non-GAAP earnings per share were $2.77. The company has reduced its 2022 financial guidance due to headwinds in the CDMO business, unfavorable foreign exchange rates and rising interest rates.
Second-quarter revenue reached $973.1 million, up 6.4% year-over-year.
GAAP earnings per share were $2.13, a 23.8% increase from Q2 2021.
Non-GAAP earnings per share were $2.77, up 6.1% compared to the previous year.
Revised 2022 financial guidance due to CDMO headwinds and unfavorable foreign exchange and interest rates.
Charles River is reducing its 2022 financial guidance due to headwinds associated with the CDMO business, foreign exchange, and interest expense.
Visualization of income flow from segment revenue to net income